메뉴 건너뛰기




Volumn 6, Issue , 2012, Pages 73-82

Lanreotide depot deep subcutaneous injection: A new method of delivery and its associated benefits

Author keywords

Acromegaly; Lanreotide; Pituitary tumor; Somatostatin analog; Treatment

Indexed keywords

ANGIOPEPTIN; LONG ACTING DRUG; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR;

EID: 84857099623     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S20783     Document Type: Review
Times cited : (20)

References (56)
  • 2
    • 49649124901 scopus 로고    scopus 로고
    • A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
    • Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89-95.
    • (2008) Eur J Endocrinol , vol.159 , Issue.2 , pp. 89-95
    • Holdaway, I.M.1    Bolland, M.J.2    Gamble, G.D.3
  • 3
    • 33845491265 scopus 로고    scopus 로고
    • Medical progress: Acromegaly
    • Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24): 2558-2573.
    • (2006) N Engl J Med , vol.355 , Issue.24 , pp. 2558-2573
    • Melmed, S.1
  • 4
    • 70449366466 scopus 로고    scopus 로고
    • Acromegaly pathogenesis and treatment
    • Nov
    • Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. Nov 2009;119(11):3189-3202.
    • (2009) J Clin Invest , vol.119 , Issue.11 , pp. 3189-3202
    • Melmed, S.1
  • 5
    • 66149130384 scopus 로고    scopus 로고
    • Guidelines for acromegaly management: An update
    • Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5): 1509-1517.
    • (2009) J Clin Endocrinol Metab , vol.94 , Issue.5 , pp. 1509-1517
    • Melmed, S.1    Colao, A.2    Barkan, A.3
  • 6
    • 15944401695 scopus 로고    scopus 로고
    • The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure"
    • Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure." Eur J Endocrinol. 2005;152(3):379-387.
    • (2005) Eur J Endocrinol , vol.152 , Issue.3 , pp. 379-387
    • Nomikos, P.1    Buchfelder, M.2    Fahlbusch, R.3
  • 7
    • 0036319414 scopus 로고    scopus 로고
    • Somatostatin analogs in acromegaly
    • Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3013-3018.
    • (2002) J Clin Endocrinol Metab , vol.87 , Issue.7 , pp. 3013-3018
    • Freda, P.U.1
  • 9
    • 76649132060 scopus 로고    scopus 로고
    • Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK)
    • Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-382.
    • (2010) Clin Endocrinol (Oxf) , vol.72 , Issue.3 , pp. 377-382
    • Fernandez, A.1    Karavitaki, N.2    Wass, J.A.3
  • 10
  • 12
    • 7244257406 scopus 로고    scopus 로고
    • Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)
    • Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439-446.
    • (2004) Eur J Endocrinol , vol.151 , Issue.4 , pp. 439-446
    • Mestron, A.1    Webb, S.M.2    Astorga, R.3
  • 14
    • 0031774361 scopus 로고    scopus 로고
    • Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
    • Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10):3419-3426.
    • (1998) J Clin Endocrinol Metab , vol.83 , Issue.10 , pp. 3419-3426
    • Swearingen, B.1    Barker II, F.G.2    Katznelson, L.3
  • 15
    • 79958150259 scopus 로고    scopus 로고
    • Current management practices for acromegaly: An international survey
    • Giustina A, Bronstein MD, Casanueva FF, et al. Current management practices for acromegaly: an international survey. Pituitary. 2011; 14(2):125-133.
    • (2011) Pituitary , vol.14 , Issue.2 , pp. 125-133
    • Giustina, A.1    Bronstein, M.D.2    Casanueva, F.F.3
  • 16
    • 0034690311 scopus 로고    scopus 로고
    • Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
    • Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-1177.
    • (2000) N Engl J Med , vol.342 , Issue.16 , pp. 1171-1177
    • Trainer, P.J.1    Drake, W.M.2    Katznelson, L.3
  • 17
    • 67650761129 scopus 로고    scopus 로고
    • Pituitary tumor size in acromegaly during pegvisomant treatment: Experience from MR re- evaluations of the German Pegvisomant Observational Study
    • Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re- evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol. 2009;161(1):27-35.
    • (2009) Eur J Endocrinol , vol.161 , Issue.1 , pp. 27-35
    • Buchfelder, M.1    Weigel, D.2    Droste, M.3
  • 18
    • 4143066821 scopus 로고    scopus 로고
    • Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status
    • Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinol (Oxf). 2004;61(2):209-215.
    • (2004) Clinical Endocrinol (Oxf) , vol.61 , Issue.2 , pp. 209-215
    • Cozzi, R.1    Attanasio, R.2    Lodrini, S.3    Lasio, G.4
  • 19
    • 64549105745 scopus 로고    scopus 로고
    • Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: Long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    • Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160(4): 529-533.
    • (2009) Eur J Endocrinol , vol.160 , Issue.4 , pp. 529-533
    • Neggers, S.J.1    de Herder, W.W.2    Janssen, J.A.3    Feelders, R.A.4    van der Lely, A.J.5
  • 20
    • 80053921557 scopus 로고    scopus 로고
    • Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    • Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. 2011;14(3):253-258.
    • (2011) Pituitary , vol.14 , Issue.3 , pp. 253-258
    • Neggers, S.J.1    de Herder, W.W.2    Feelders, R.A.3    van der Lely, A.J.4
  • 21
    • 15944427116 scopus 로고    scopus 로고
    • Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly
    • Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrin Metab. 2005; 90(3):1856-1863.
    • (2005) J Clin Endocrin Metab , vol.90 , Issue.3 , pp. 1856-1863
    • Bevan, J.S.1
  • 22
    • 69949103972 scopus 로고    scopus 로고
    • Long-term results of stereotactic radiosurgery in secretory pituitary adenomas
    • Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrin Metab. 2009;94(9):3400-3407.
    • (2009) J Clin Endocrin Metab , vol.94 , Issue.9 , pp. 3400-3407
    • Castinetti, F.1    Nagai, M.2    Morange, I.3
  • 23
    • 77954845856 scopus 로고    scopus 로고
    • Mortality in patients with pituitary disease
    • Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-342.
    • (2010) Endocr Rev , vol.31 , Issue.3 , pp. 301-342
    • Sherlock, M.1    Ayuk, J.2    Tomlinson, J.W.3
  • 24
    • 1942473114 scopus 로고    scopus 로고
    • Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly
    • Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89(4):1613-1617.
    • (2004) J Clin Endocrinol Metab , vol.89 , Issue.4 , pp. 1613-1617
    • Ayuk, J.1    Clayton, R.N.2    Holder, G.3    Sheppard, M.C.4    Stewart, P.M.5    Bates, A.S.6
  • 25
    • 77949314882 scopus 로고    scopus 로고
    • Pituitary somatostatin receptor signaling
    • Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21(3):123-133.
    • (2010) Trends Endocrinol Metab , vol.21 , Issue.3 , pp. 123-133
    • Ben-Shlomo, A.1    Melmed, S.2
  • 27
    • 24344455912 scopus 로고    scopus 로고
    • Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel
    • Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism. 2005;54(10):1276-1281.
    • (2005) Metabolism , vol.54 , Issue.10 , pp. 1276-1281
    • Cendros, J.M.1    Peraire, C.2    Troconiz, I.F.3    Obach, R.4
  • 28
    • 0242361163 scopus 로고    scopus 로고
    • Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans
    • Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut. 2003;52(11):1555-1561.
    • (2003) Gut , vol.52 , Issue.11 , pp. 1555-1561
    • Foxx-Orenstein, A.1    Camilleri, M.2    Stephens, D.3    Burton, D.4
  • 29
    • 84857071971 scopus 로고    scopus 로고
    • Ipsen Pharmacueticals Somatuline Depot (Lanreotide) injection US prescribing information
    • Ipsen Pharmacueticals Somatuline Depot (Lanreotide) injection US prescribing information, 2011.
    • (2011)
  • 30
    • 11144357696 scopus 로고    scopus 로고
    • Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers
    • Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol. 2004;56(4):471-476.
    • (2004) J Pharm Pharmacol , vol.56 , Issue.4 , pp. 471-476
    • Antonijoan, R.M.1    Barbanoj, M.J.2    Cordero, J.A.3
  • 31
    • 27744591469 scopus 로고    scopus 로고
    • Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days
    • Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63(5):514-519.
    • (2005) Clin Endocrinol (Oxf) , vol.63 , Issue.5 , pp. 514-519
    • Bronstein, M.1    Musolino, N.2    Jallad, R.3
  • 32
    • 57449121822 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: Evidence for injection interval of up to 2 months
    • Troconiz IF, Cendros JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48(1):51-62.
    • (2009) Clin Pharmacokinet , vol.48 , Issue.1 , pp. 51-62
    • Troconiz, I.F.1    Cendros, J.M.2    Peraire, C.3
  • 34
    • 49249113074 scopus 로고    scopus 로고
    • A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
    • Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-2968.
    • (2008) J Clin Endocrinol Metab , vol.93 , Issue.8 , pp. 2957-2968
    • Murray, R.D.1    Melmed, S.2
  • 35
    • 4744375607 scopus 로고    scopus 로고
    • Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR
    • Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. E J Endocrinol. 2004;151(3):317-324.
    • (2004) E J Endocrinol , vol.151 , Issue.3 , pp. 317-324
    • Alexopoulou, O.1    Abrams, P.2    Verhelst, J.3
  • 36
    • 39149133993 scopus 로고    scopus 로고
    • A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly
    • Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol. 2008;68(3):473-480.
    • (2008) Clin Endocrinol , vol.68 , Issue.3 , pp. 473-480
    • Andries, M.1    Glintborg, D.2    Kvistborg, A.3    Hagen, C.4    Andersen, M.5
  • 37
    • 2342653531 scopus 로고    scopus 로고
    • The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR
    • Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. E J Endocrinol. 2004;150(4):473-480.
    • (2004) E J Endocrinol , vol.150 , Issue.4 , pp. 473-480
    • Ashwell, S.G.1    Bevan, J.S.2    Edwards, O.M.3
  • 38
    • 0036148030 scopus 로고    scopus 로고
    • Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly
    • Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrin Metab. 2002;87(1):99-104.
    • (2002) J Clin Endocrin Metab , vol.87 , Issue.1 , pp. 99-104
    • Caron, P.1    Beckers, A.2    Cullen, D.R.3
  • 39
    • 2942701886 scopus 로고    scopus 로고
    • One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel
    • Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol. 2004;60(6):734-740.
    • (2004) Clin Endocrinol , vol.60 , Issue.6 , pp. 734-740
    • Caron, P.1    Bex, M.2    Cullen, D.R.3
  • 40
    • 67650317928 scopus 로고    scopus 로고
    • Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
    • Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol(Oxf). 2009;71(2):237-245.
    • (2009) Clin Endocrinol(Oxf) , vol.71 , Issue.2 , pp. 237-245
    • Colao, A.1    Auriemma, R.S.2    Rebora, A.3
  • 41
    • 41349117707 scopus 로고    scopus 로고
    • Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
    • Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol. 2008;69(2):299-305.
    • (2008) Clin Endocrinol , vol.69 , Issue.2 , pp. 299-305
    • Chanson, P.1    Borson-Chazot, F.2    Kuhn, J.M.3    Blumberg, J.4    Maisonobe, P.5    Delemer, B.6
  • 42
    • 33747374573 scopus 로고    scopus 로고
    • Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
    • Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006;65(3):320-326.
    • (2006) Clin Endocrinol (Oxf) , vol.65 , Issue.3 , pp. 320-326
    • Lucas, T.1    Astorga, R.2
  • 43
    • 77949274556 scopus 로고    scopus 로고
    • Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: A randomized, placebo-controlled, multicenter study with a 52 week open extension
    • Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18-28.
    • (2010) Pituitary , vol.13 , Issue.1 , pp. 18-28
    • Melmed, S.1    Cook, D.2    Schopohl, J.3    Goth, M.I.4    Lam, K.S.5    Marek, J.6
  • 44
    • 34548665710 scopus 로고    scopus 로고
    • Efficacy of a slowrelease formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): An open, multicentre longitudinal study
    • Ronchi CL, Boschetti M, Degli Uberti EC, et al. Efficacy of a slowrelease formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67(4):512-519.
    • (2007) Clin Endocrinol (Oxf) , vol.67 , Issue.4 , pp. 512-519
    • Ronchi, C.L.1    Boschetti, M.2    Degli Uberti, E.C.3
  • 45
    • 70350324543 scopus 로고    scopus 로고
    • Eff icacy of long-term lanreotide treatment in patients with acromegaly
    • Toledano Y, Rot L, Greenman Y, et al. Eff icacy of long-term lanreotide treatment in patients with acromegaly. Pituitary. 2009;12(4): 285-293.
    • (2009) Pituitary , vol.12 , Issue.4 , pp. 285-293
    • Toledano, Y.1    Rot, L.2    Greenman, Y.3
  • 46
    • 17144431786 scopus 로고    scopus 로고
    • Four-year Follow-up of Acromegalic Patients Treated With the New Long-acting Formulation of Lanreotide (Lanreotide Autogel)
    • Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes. 2005;113(3):139-144.
    • (2005) Exp Clin Endocrinol Diabetes , vol.113 , Issue.3 , pp. 139-144
    • Gutt, B.1    Bidlingmaier, M.2    Kretschmar, K.3    Dieterle, C.4    Steffin, B.5    Schopohl, J.6
  • 47
    • 33645025605 scopus 로고    scopus 로고
    • Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly
    • Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol. 2006;64(2):209-214.
    • (2006) Clin Endocrinol , vol.64 , Issue.2 , pp. 209-214
    • Caron, P.1    Cogne, M.2    Raingeard, I.3    Bex-Bachellerie, V.4    Kuhn, J.M.5
  • 48
    • 33746273283 scopus 로고    scopus 로고
    • Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly
    • Jul
    • Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. Jul 2006;155(1):73-78.
    • (2006) Eur J Endocrinol , vol.155 , Issue.1 , pp. 73-78
    • Steffin, B.1    Gutt, B.2    Bidlingmaier, M.3    Dieterle, C.4    Oltmann, F.5    Schopohl, J.6
  • 49
    • 0036205121 scopus 로고    scopus 로고
    • Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly
    • Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146(3):303-309.
    • (2002) Eur J Endocrinol , vol.146 , Issue.3 , pp. 303-309
    • Colao, A.1    Marzullo, P.2    Lombardi, G.3
  • 50
    • 36549054677 scopus 로고    scopus 로고
    • Optimalization and cost management of lanreotide-Autogel therapy in acromegaly
    • Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol. 2007;157(5):571-577.
    • (2007) Eur J Endocrinol , vol.157 , Issue.5 , pp. 571-577
    • Abrams, P.1    Alexopoulou, O.2    Abs, R.3    Maiter, D.4    Verhelst, J.5
  • 51
    • 77955877150 scopus 로고    scopus 로고
    • Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly
    • Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115-122.
    • (2010) Pituitary , vol.13 , Issue.2 , pp. 115-122
    • Salvatori, R.1    Nachtigall, L.B.2    Cook, D.M.3
  • 52
    • 39149094648 scopus 로고    scopus 로고
    • Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective
    • Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol. 2008;68(3):343-349.
    • (2008) Clin Endocrinol , vol.68 , Issue.3 , pp. 343-349
    • Bevan, J.S.1    Newell-Price, J.2    Wass, J.A.3
  • 53
    • 79952440348 scopus 로고    scopus 로고
    • Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously: Treated with octreotide LAR
    • Schopohl J, Strasburger CJ, Caird D, et al. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously: treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011;119(3):156-162.
    • (2011) Exp Clin Endocrinol Diabetes , vol.119 , Issue.3 , pp. 156-162
    • Schopohl, J.1    Strasburger, C.J.2    Caird, D.3
  • 56
    • 59749084581 scopus 로고    scopus 로고
    • The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly
    • Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523-527.
    • (2009) J Clin Endocrinol Metab , vol.94 , Issue.2 , pp. 523-527
    • Carmichael, J.D.1    Bonert, V.S.2    Mirocha, J.M.3    Melmed, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.